Patents by Inventor Sreekanth Ramachandran

Sreekanth Ramachandran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods of use
    Patent number: 11702401
    Abstract: This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF?) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
    Type: Grant
    Filed: May 22, 2021
    Date of Patent: July 18, 2023
    Assignee: Medivation Technologies LLC
    Inventors: Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230066315
    Abstract: Compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Application
    Filed: January 17, 2020
    Publication date: March 2, 2023
    Inventors: Son Minh PHAM, Jayakanth KANKANALA, Pradeep S. JADHAVAR, Baban Mohan MULIK, Farha KHAN, Sreekanth A. RAMACHANDRAN
  • HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
    Publication number: 20220298142
    Abstract: 5,6-disubstituted 2-aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Application
    Filed: March 2, 2022
    Publication date: September 22, 2022
    Inventors: Son Minh PHAM, Jayakanth KANKANALA, Pradeep S. JADHAVAR, Baban Mohan MULIK, Farha KHAN, Sreekanth A. RAMACHANDRAN
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF
    Publication number: 20220281842
    Abstract: The present disclosure relates generally to compounds useful in treatment of conditions associated with Checkpoint kinase (CHK), particularly CHK-1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against CHK-1 enzymes. Methods of treating conditions associated with excessive activity of CHK-1 enzymes with such compounds is disclosed. Uses thereof, pharmaceutical compositions, kits and method of synthesis also disclosed.
    Type: Application
    Filed: July 31, 2020
    Publication date: September 8, 2022
    Inventors: Dhananjay Pendharkar, Sreekanth A. Ramachandran, Pradeep S. Jadhavar, Dayanand Panpatil, Uzma Saeed, Vivek Kumar, Dipshe Bist
  • 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF
    Publication number: 20220220111
    Abstract: 1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Application
    Filed: December 13, 2021
    Publication date: July 14, 2022
    Inventors: Son Minh Phan, Jiyun Chen, Amantullah Ansari, Pradeep S. Jadhavar, Varshavekumar S. Patil, Farha Khan, Sreekanth A. Ramachandran, Anil Kumar Agarwal, Sarvajit Chakravarty
  • 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF
    Publication number: 20220169648
    Abstract: 1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Application
    Filed: February 18, 2022
    Publication date: June 2, 2022
    Inventors: Son Minh PHAM, Jayakanth KANKANALA, Pradeep S. JADHAVAR, Baban Mohan MULIK, Farha KHAN, Sreekanth A. RAMACHANDRAN
  • ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF
    Publication number: 20220135598
    Abstract: The present invention discloses compounds useful in treatment of conditions associated with dysfunction of ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) enzyme. Specifically, the present invention discloses compound of formula (J) which exhibit inhibitory activity against ENPP1. Method of treating conditions associated with over-expression of ENPP1 gene with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.
    Type: Application
    Filed: November 1, 2021
    Publication date: May 5, 2022
    Inventors: Brahmam Pujala, Amantullah Ansari, Shreya Sapra, Pradeep S. Jadhavar, Dhananjay Pendharkar, Sreekanth A. Ramachandran, Uzma Saeed, Abhinandan Danodia, Farha Khan, Sagar Patni, Sanjeev Soni, Ashu Gupta, Sarvajit Chakravarty, Balaji Dashrath Sathe
  • HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
    Publication number: 20220119367
    Abstract: Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Application
    Filed: January 17, 2020
    Publication date: April 21, 2022
    Inventors: Son Minh PHAM, Jayakanth KANKANALA, Pradeep S. JADHAVAR, Baban Mohan MULIK, Farha KHAN, Sreekanth A. RAMACHANDRAN
  • Heterocyclic compounds as adenosine antagonists
    Patent number: 11306071
    Abstract: 5,6-disubstituted 2-aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: April 19, 2022
    Assignee: Nuvation Bio Inc.
    Inventors: Son Minh Pham, Jayakanth Kankanala, Pradeep S. Jadhavar, Baban Mohan Mulik, Farha Khan, Sreekanth A. Ramachandran
  • 1,8-naphthyridinone compounds and uses thereof
    Patent number: 11254670
    Abstract: 1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: February 22, 2022
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Jayakanth Kankanala, Pradeep S. Jadhavar, Baban Mohan Mulik, Farha Khan, Sreekanth A. Ramachandran
  • Compounds and Methods of Use
    Publication number: 20220000847
    Abstract: This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF?) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
    Type: Application
    Filed: May 22, 2021
    Publication date: January 6, 2022
    Applicant: Medivation Technologies LLC
    Inventors: Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
  • HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
    Publication number: 20210292285
    Abstract: Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Application
    Filed: February 12, 2021
    Publication date: September 23, 2021
    Inventors: Son Minh PHAM, Jiyun CHEN, Amantullah ANSARI, Pradeep S. JADHAVAR, Varshavekumar S. PATIL, Farha KHAN, Sreekanth A. RAMACHANDRAN, Anil Kumar AGARWAL, Sarvajit CHAKRAVARTY
  • Compounds and methods of use
    Patent number: 11053216
    Abstract: This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF?) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: July 6, 2021
    Assignee: Medivation Technologies LLC
    Inventors: Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
  • Heterocyclic compounds as adenosine antagonists
    Patent number: 11028058
    Abstract: Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: June 8, 2021
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Jiyun Chen, Amantullah Ansari, Pradeep S. Jadhavar, Varshavekumar S. Patil, Farha Khan, Sreekanth A. Ramachandran, Anil Kumar Agarwal, Sarvajit Chakravarty
  • 1,8-naphthyridinone compounds and uses thereof
    Patent number: 10793561
    Abstract: 1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: October 6, 2020
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Jiyun Chen, Amantullah Ansari, Pradeep S. Jadhavar, Varshavekumar S. Patil, Farha Khan, Sreekanth A. Ramachandran, Anil Kumar Agarwal, Sarvajit Chakravarty
  • 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF
    Publication number: 20200231589
    Abstract: 1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Application
    Filed: January 17, 2020
    Publication date: July 23, 2020
    Inventors: Son Minh PHAM, Jayakanth KANKANALA, Pradeep S. JADHAVAR, Baban Mohan MULIK, Farha KHAN, Sreekanth A. RAMACHANDRAN
  • HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
    Publication number: 20200231570
    Abstract: Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Application
    Filed: January 17, 2020
    Publication date: July 23, 2020
    Inventors: Son Minh PHAM, Jayakanth KANKANALA, Pradeep S. JADHAVAR, Baban Mohan MULIK, Farha KHAN, Sreekanth A. RAMACHANDRAN
  • HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS
    Publication number: 20200206233
    Abstract: The present disclosure relates generally to compounds useful in treatment of conditions associated with mutant isocitrate dehydrogenase (mt-IDH), particularly mutant IDH1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against mutant IDH1 enzymes. Method of treating conditions associated with excessive activity of mutant IDH1 enzymes with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.
    Type: Application
    Filed: December 30, 2019
    Publication date: July 2, 2020
    Inventors: Sarvajit CHAKRAVARTY, Dhananjay PENDHARKAR, Sreekanth A. RAMACHANDRAN, Chandramohan BATHULA, Sanjeev SONI, Vivek KUMAR, Uzma SAEED, Abhinandan Kumar DANODIA, Ankesh SHARMA, Pradeep S. JADHAVAR
  • DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE
    Publication number: 20200171030
    Abstract: The present disclosure generally relates to the compounds that exhibits protein kinase inhibitory activity. Specifically, the present disclosure provides compounds of formula (I) that exhibits dual inhibitory activity against ALK5 and P38A MAP kinase. The present disclosure also provides process(es) for preparation of such compounds, pharmaceutical compositions containing one or a combination of these compounds, and methods of treatment of conditions associated with excessive activity of any or a combination of transforming growth factor-beta (TGF?) and p38 mitogen-activated protein kinase (MAPK) utilizing these compounds. An aspect of the present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salt, polymorph, solvate or stereoisomer thereof that exhibit dual inhibitory activity against ALK5 and P38 alpha.
    Type: Application
    Filed: January 17, 2019
    Publication date: June 4, 2020
    Inventors: Sarvajit CHAKRAVARTY, Dhananjay PENDHARKAR, Dilip V. JARIKOTE, Bhausaheb B. BHAGWAT, Anil K. AGARWAL, Brahmam PUJALA, Sreekanth A. RAMACHANDRAN, Sagar PATNI
  • Compounds and Methods of Use
    Publication number: 20200071296
    Abstract: This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF?) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
    Type: Application
    Filed: October 22, 2019
    Publication date: March 5, 2020
    Inventors: Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Naveen Chaklan, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham